2Bailey DC, Bondar A, Furness LM. Pharmacogenomics - it' s not just pharmacogenomics. Curr Opin Biotechnol, 1998, 9(6) :595 - 601
3Baudin B. Angiotensin Ⅱ receptor polymorphisms in hypertension. Pharmacogenomic considerations. Pharmacogenomics, 2002,3 (1): 65 - 73
4Rioux PP. Clinical trails in pharmacogenomics and pharmacogenetics: methods and applications. Am J Health Syst Pharma, 2000,57(9) :887
5Yamada M. Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients. J Atheroscler Thromb, 1997,4 ( 1 ): 40 - 44
6Hancox RJ, Sears MR, Taylor DR. Polymorphism of the beta 2- adrenoceptor and response to long- term beta 2 - agonist therapy in asthma. Eur Respir J, 1998,11(3) :589 - 593
7Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci,2001,6:298 - 302
8Murphy MP, Beaman ME, Clark LS et al. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase Ⅲ clinical trail. Pharmacogenetics, 2000, 7: 583- 588
9Cargill M,Daley CQ.Mining for SNPs:putting the common variants- common disease hypothesis to the test. Pharmacogenomics, 2000,1 (1) :27 - 37
10Winkelmann BR. Genomics and large scale phenotypic databases. Pharmacogenomics, 2001,2(1): 3 - 5
同被引文献20
1Boumendjel A, Di Pietro A, Dumontet C, Barron D. Becent advances in the discovery of flavonoids and analogs with high - affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev, 2002, 22(5): 512 ～29.
2Bleicher K. H, . Bohm H. J, Muller K., Alanine A. I.. Hit and lead generation: beyond high -throughput screening. NatureReviews Drug Discovery. 2003, 2:369 ～ 378.
3Verkman A. S. Drug discovery in academi. Am J Physiol Cell Physiol 2004, 286:465 - 474.
4Davidov E, Holland J, Marple E, Naylor S. Advancing drug discovery through systems biology. Drug Discov Today, 2003, 8 (4): 175 ～ 83.
5Drews J. Drug Discovery: A Historical Perspective. Science. 2000,287:1960 - 1964.
6Lindsay M. A. Target discovery. Nature Reviews Drug Discovery. 2003,2:831 ～ 838.
7Roses A.D. Genome - based pharmacogenetics and the pharmaceutical industry. Nature Reviews Drug Discovery. 2002, 1:541 ～549.
8McCarthy J. J. Advances in pharmacogenomic research and development.Mol Biotechnol, 2003, 25(3): 275 ～ 82.
9Harper G, Pickett S. D, Green D. V. S. Design of a compound screening collection for use in high throughput screening. Combinatorial Chemistry and High throughput screening. 2004, 7:63 ～ 70.
10Smith C. Drug target validation: Hitting the target. Nature, 2003, 422:341 - 347.
